Stockreport

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Marinus Pharmaceuticals, Inc.  (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations
PDF Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganax [Read more]